Cytocom statera
WebJul 27, 2024 · Cytocom, Inc. completed the acquisition of Cleveland BioLabs, Inc. in a reverse merger transaction. MarketScreener Homepage Equities United States OTC Markets Statera Biopharma, Inc. News Summary STAB US8575611046 STATERA BIOPHARMA, INC. (STAB) Add to my list Company Funds WebOct 27, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers...
Cytocom statera
Did you know?
WebAug 31, 2024 · Cytocom, Inc. Nichol Ochsner Senior V.P. Investor Relations and Corporate Communications (732) 754-2545 [email protected] Tiberend Strategic Advisors, Inc. Maureen McEnroe, CFA (Investors) (212) 375-2664 [email protected] Johanna Bennett (Media) (212) 375-2686 [email protected] WebFeb 22, 2024 · Statera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and ...
WebSep 7, 2024 · Cytocom acquired ImQuest Life Science, Inc. in an all-stock deal on June 23, 2024, and provided an update on its integration on September 1. Together, these entities will strengthen and expand... WebMay 13, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers ...
WebAug 29, 2024 · 29 Aug 2024 by Datacenters.com Colocation. Ashburn, a city in Virginia’s Loudoun County about 34 miles from Washington D.C., is widely known as the Data … WebSep 28, 2024 · Cytocom issued the 125,000 shares of its common stock on March 4, 2024. Due to the fact that Cytocom did not have sufficient funds by January 25, 2024, it was unable to meet its payment obligations to Ira Gaines and the Gaines Trust due on that date. The $50,000 payment was made on June 9, 2024.
WebOct 6, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers ...
WebUNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 pmi tallahasseeWebAug 31, 2024 · FORT COLLINS, Colo., Aug. 31, 2024 — Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that … pmi summaryWebFeb 22, 2024 · Statera Biopharma (NASDAQ: STAB), formerly known as "Cytocom," has reported prelim revenue of $1.49M for 2024. The biopharmaceutical firm reported no revenue in 2024. The growth in revenue was ... pmi sunnysideWebUntil the transaction is completed, Cytocom (now, Statera Biopharma, Inc.) does not have a clear title and interest to our Company’s technology. In March 2024, the Company and Cytocom negotiated an amendment to the licensing agreement (“Third License Amendment”) which has been submitted to the board of directors of Cytocom for approval. pmi tailleWebAug 5, 2024 · Cytocom is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby … pmi sustainabilityWebApr 12, 2024 · Statera Biopharma granted continued listing on Nasdaq Benzinga 126d Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving … pmi taken offWebFeb 18, 2024 · Feb. 18, 2024 1:14 AM ET Statera Biopharma, Inc. (STAB) STAB By: ... (CBLI)soars 27%after-hours after filing Form S-4 with the SEC in connection with its merger agreement with Cytocom pmi suisse